Psoriasis, a chronic immune-mediated inflammatory
skin disease, influences approximately 2-3% of the world's population. At present, the etiology of
psoriasis remains unclear and there is still no causal treatment available. Recent studies indicate that oxidative stress (OS) and T cells dysregulation may participate in the pathogenesis of
psoriasis, among which M1-dominant macrophage polarization is a crucial contributor. Macrophages mainly polarize into two different subsets, ie, classically activated macrophage (M1) and alternatively activated macrophage (M2). M1 polarization tends to exacerbate
psoriasis via producing substantial
reactive oxygen species (ROS) and inflammatory mediators, to encourage OS invasion and T cells dysregulation. Thus, targeting M1 polarization can be a possible therapeutic alternative for
psoriasis.
Loganin, belonging to
iridoid glycosides, is a pharmaceutically active ingredient originated from Cornus officinalis, exerting multiple
biological activities, eg,
immunomodulation, antioxidation, anti-
inflammation, etc. More importantly, it could effectively suppress M1 polarization, thereby arresting OS aggression and T cells' dysregulation. Numerous studies have confirmed that
loganin is quite reliable for diseases treatment via suppressing M1 polarization. Nevertheless, reports about
loganin treating
psoriasis have seldom appeared so far. Accordingly, we hold a hypothesis that
loganin would availably manage
psoriasis through preventing M1 polarization. Data from previous studies guarantee the potential of
loganin in control of
psoriasis.